Bleximenib, for instance, is currently being tested in a pediatric cohort (12 years and older) of the phase 1/2 study (cAMeLot-1) for acute leukemia patients harboring KMT2A, NPM1, NUP98, or NUP214 alterations (NCT04811560). This evidence concerns the gene NUP214 and acute leukemia.